LUNG
Pulmonx CorporationNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.04
P/S
0.63
EV/EBITDA
-0.86
DCF Value
$-14.43
FCF Yield
-57.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
74.2%
Operating Margin
-59.3%
Net Margin
-59.7%
ROE
-82.8%
ROA
-41.8%
ROIC
-48.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $22.6M | $-10.4M | $-0.25 |
| FY 2025 | $90.5M | $-54.0M | $-1.33 |
| Q3 2025 | $21.5M | $-14.0M | $-0.34 |
| Q2 2025 | $23.9M | $-15.2M | $-0.38 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.19
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.